Investigating PF-06821497 for men with advanced prostate cancer
Official title: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
Run by Pfizer · NCT06551324 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if a new medicine called PF-06821497, when combined with enzalutamide, can help men with advanced prostate cancer live longer without their cancer getting worse compared to standard treatments.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 600 (estimated) |
| Sponsor | Pfizer Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 175 sites (Homewood, Alabama and 174 other locations) |
| Trial ID | NCT06551324 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men with histologically confirmed adenocarcinoma of the prostate who have metastatic disease and have shown disease progression after treatment with abiraterone acetate.
✕Probably not a fit
Patients with small cell features of prostate cancer or those with significant comorbidities that may interfere with participation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the safety and effectiveness of the investigational medicine PF-06821497 when combined with enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC) who have previously been treated with abiraterone acetate. Participants will be randomly assigned to receive either the combination treatment or a physician's choice of second-line therapy, which may include enzalutamide or docetaxel. The primary goal is to assess the radiographic progression-free survival (rPFS) of the combination therapy compared to the standard treatments.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for men with advanced prostate cancer who have limited options after prior therapies.
How similar studies have gone: Other studies have shown promise with similar combination therapies in treating advanced prostate cancer, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. * Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan. * Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required. * Eastern Cooperate Oncology Group (ECOG) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator. Exclusion Criteria: * Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study. * Know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery. * Clinically significant cardiovascular disease. * Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure. * Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177Lu-PSMA-617, radium 223), androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment, with the following exceptions: 1. Treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention. 2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion. * Previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is shorter). * Inadequate organ function.
Where it's running
-
Urology Centers of Alabama
Homewood, Alabama, United States Recruiting -
Arizona Urology Specialists- Provide ICF for Review Only
Tucson, Arizona, United States Recruiting -
Arizona Urology Specialists (AUS)-Orange Grove
Tucson, Arizona, United States Recruiting -
Sutter Santa Rosa
Santa Rosa, California, United States Recruiting -
Colorado Clinical Research
Lakewood, Colorado, United States Recruiting -
Florida Cancer Specialists
Bonita Springs, Florida, United States Recruiting
Show 44 more locations
-
Florida Cancer Specialists
Bradenton, Florida, United States Recruiting -
Florida Cancer Specialists
Cape Coral, Florida, United States Recruiting -
Florida Cancer Specialists
Fort Myers, Florida, United States Recruiting -
Florida Cancer Specialists
Fort Myers, Florida, United States Recruiting -
Florida Cancer Specialists
Naples, Florida, United States Recruiting -
Florida Cancer Specialists
Port Charlotte, Florida, United States Recruiting -
Florida Cancer Specialists
Sarasota, Florida, United States Recruiting -
Florida Cancer Specialists
Venice, Florida, United States Recruiting -
Duly Health and Care
Hinsdale, Illinois, United States Recruiting -
Duly Health And Care
Lisle, Illinois, United States Recruiting -
NextStage Clinical Research-Chicago-(04)
Lisle, Illinois, United States Recruiting -
Duly Health and Care
Westmont, Illinois, United States Recruiting -
AtlantiCare
Egg Harbor Township, New Jersey, United States Recruiting -
Keystone Urology Specialists
Lancaster, Pennsylvania, United States Recruiting -
SCRI Oncology Partners
Nashville, Tennessee, United States Recruiting -
USA Clinical Trials
San Antonio, Texas, United States Recruiting -
Huntsman Cancer Institute
Salt Lake City, Utah, United States Recruiting -
Centro de Urología (CDU)
Caba, Buenos Aires, Argentina Recruiting -
Hospital Sirio Libanes
Capital Federal, Buenos Aires, Argentina Recruiting -
Imagenes Mdq
Mar del Plata, Buenos Aires, Argentina Recruiting -
Instituto de Investigaciones Clínicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina Recruiting -
Centro Medico Privado CEMAIC
Capital, Córdoba, Argentina Recruiting -
Imaxe
Buenos Aires, Argentina Recruiting -
Asociación de Beneficencia Hospital Sirio Libanés
Buenos Aires, Argentina Recruiting -
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia Recruiting -
Monash Health
Clayton, Victoria, Australia Recruiting -
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia Recruiting -
Hospital São Lucas da PUCRS
Porto Alegre, RIO Grande DO SUL, Brazil Recruiting -
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
Santo André, SÃO Paulo, Brazil Recruiting -
Hospital Alemao Oswaldo Cruz
Sao Paulo, SÃO Paulo, Brazil Recruiting -
Instituto do Cancer Arnaldo Vieira de Carvalho
São Paulo, Brazil Recruiting -
IBCC - Núcleo de Pesquisa e Ensino
São Paulo, Brazil Recruiting -
Chongqing University Cancer Hospital
Chongqing, Chongqing, China Recruiting -
Fujian Cancer Hospital
Fuzhou, Fujian, China Recruiting -
Lanzhou university second hospital
Lanzhou, Gansu, China Recruiting -
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China Recruiting -
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting -
Hunan Cancer Hospital
Changsha, Hunan, China Recruiting -
Nantong Tumor Hospital
Nantong, Jiangsu, China Recruiting -
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China Recruiting -
The First Hospital of China Medical University
Shenyang, Liaoning, China Recruiting -
The First Hospital of China Medical University
Shenyang, Liaoning, China Recruiting -
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China Recruiting -
Shaanxi Provincial People' Hospital
Xi'an, Shaanxi, China Recruiting
+125 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SX-682 combined with apalutamide for advanced prostate cancer no longer responding to hormone therapy.
This trial will test whether adding SX-682 to apalutamide helps men with metastatic castration‑resistant prostate cancer who have progressed after another next‑generation antiandrogen.
-
Personalized versus fixed‑dose Lutetium‑177 PSMA therapy for metastatic castration‑resistant prostate cancer
This study will test whether personalizing Lutetium‑177 PSMA dosing using kidney dosimetry lets men with metastatic castration‑resistant prostate cancer safely receive higher treatment activity than the standard fixed dosing.
-
Impact of 177Lu-PSMA therapy on kidney function in prostate cancer patients
This study is testing how a new prostate cancer treatment affects kidney function in men with advanced prostate cancer over five years.
-
GI-102 with Pasritamig for metastatic prostate cancer
This trial tests GI-102 together with Pasritamig to see if it is safe and may help men whose metastatic castration-resistant prostate cancer has progressed after prior hormonal therapy.
-
Exploring Terbium-161 PSMA Therapy for Advanced Prostate Cancer
This phase 1 study tests 161Tb-PSMA-I&T to see if it is safe and how it behaves in Taiwanese men with metastatic castration-resistant prostate cancer.
-
REGN15505 Alone or With Cemiplimab or REGN4336 in Advanced Prostate Cancer and Kidney Cancer
This trial tests REGN15505 by itself or with cemiplimab or REGN4336 to see if it helps adults with metastatic castration-resistant prostate cancer or clear cell renal cell carcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.